Clinical Trials Browser

NCT06709859 2025-07-17

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Phase 2 Recruiting

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05298176 2025-03-28

COMBINATION

Phase 2 Completed

5 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02597946 2025-02-19

Afatinib in NSCLC With HER2 Mutation

Phase 2 Completed

18 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05215548 2025-02-19

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

Phase 2 Active not recruiting

100 enrolled

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT01542437 2024-02-06

NSCLC

Phase 2 Completed

66 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT02183883 2023-11-29

DARWIN1

Phase 2 Completed

12 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03727724 2023-10-18

AFACET

Phase 2 Completed

37 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

400 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02716311 2022-08-11

ACE-Lung

Phase 2 Completed

118 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01156545 2022-04-06

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

Phase 2 Completed

68 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02747953 2021-03-19

Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

Phase 2 Completed

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03157089 2021-02-23

LUX-Lung-IO

Phase 2 Completed

24 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01746251 2020-07-07

Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation

Phase 2 Unknown

92 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02271906 2019-04-30

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

Phase 2 Terminated

2 enrolled 8 charts

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT01415011 2019-01-15

TIMELY

Phase 2 Completed

39 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00525148 2016-09-16

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Phase 2 Completed

129 enrolled 18 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02470065 2016-01-22

REMNANT

Phase 2 Suspended

38 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02625168 2015-12-09

Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC

Phase 2 Completed

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00711594 2015-01-15

LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Phase 2 Completed

74 enrolled 23 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00796549 2014-07-22

BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients

Phase 2 Completed

70 enrolled 15 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00730925 2014-03-26

Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients

Phase 2 Completed

41 enrolled 9 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01003899 2013-12-31

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

Phase 2 Completed

43 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung